Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P ESCUDERO

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|March 23, 2006
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerJ Feliu, A Salud, P Escudero, et al.
Sarcoma|June 4, 2008
Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)A Poveda, A López-Pousa, J Martín, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.
British Journal of Cancer|April 15, 2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II studyJ Feliu, A Salud, P Escudero, et al.
British Journal of Cancer|June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyJ Feliu, A Salud, M J Safont, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trialEstela Pineda, A Salud, E Vila-Navarro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancerM J Sotelo, J Sastre, M L Maestro, et al.
Medicina Intensiva|March 1, 2022
ADENI-UCI study: Analysis of non-income decisions in ICU as a measure of limitation of life support treatmentsP Escudero-Acha, O Leizaola, N Lázaro, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|March 23, 2006
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerJ Feliu, A Salud, P Escudero, et al.
Sarcoma|June 4, 2008
Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)A Poveda, A López-Pousa, J Martín, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.
British Journal of Cancer|April 15, 2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II studyJ Feliu, A Salud, P Escudero, et al.
British Journal of Cancer|June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyJ Feliu, A Salud, M J Safont, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trialEstela Pineda, A Salud, E Vila-Navarro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancerM J Sotelo, J Sastre, M L Maestro, et al.
Medicina Intensiva|March 1, 2022
ADENI-UCI study: Analysis of non-income decisions in ICU as a measure of limitation of life support treatmentsP Escudero-Acha, O Leizaola, N Lázaro, et al.
Pageof 11